Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype
Top Cited Papers
- 1 October 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (10), 1844-1859
- https://doi.org/10.2215/cjn.02210310
Abstract
Background and objectives: Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Most childhood cases are caused by Shiga toxin–producing bacteria. The other form, atypical HUS (aHUS), accounts for 10% of cases and has a poor prognosis. Genetic complement abnormalities have been found in aHUS. Design, setting, participants, and measurements: We screened 273 consecutive patients with aHUS for complement abnormalities and studied their role in predicting clinical phenotype and response to treatment. We compared mutation frequencies and localization and clinical outcome in familial (82) and sporadic (191) cases. Results: In >70% of sporadic and familial cases, gene mutations, disease-associated factor H (CFH) polymorphisms, or anti-CFH autoantibodies were found. Either mutations or CFH polymorphisms were also found in the majority of patients with secondary aHUS, suggesting a genetic predisposition. Familial cases showed a higher prevalence of mutations in SCR20 of CFH and more severe disease than sporadic cases. Patients with CFH or THBD (thrombomodulin) mutations had the earliest onset and highest mortality. Membrane-cofactor protein (MCP) mutations were associated with the best prognosis. Plasma therapy induced remission in 55 to 80% of episodes in patients with CFH, C3, or THBD mutations or autoantibodies, whereas patients with CFI (factor I) mutations were poor responders. aHUS recurred frequently after kidney transplantation except for patients with MCP mutations. Conclusions: Results underline the need of genetic screening for all susceptibility factors as part of clinical management of aHUS and for identification of patients who could safely benefit from kidney transplant.Keywords
This publication has 48 references indexed in Scilit:
- Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndromeBlood, 2010
- Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndromePediatric Nephrology, 2009
- Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Thrombomodulin Mutations in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2009
- Soluble Thrombomodulin Protects Ischemic KidneysJournal of the American Society of Nephrology, 2009
- Mutations in complement C3 predispose to development of atypical hemolytic uremic syndromeBlood, 2008
- Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutationPediatric Nephrology, 2008
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Atypical Haemolytic Uraemic Syndrome Associated with a Hybrid Complement GenePLoS Medicine, 2006
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006